Evaxion Biotech's Groundbreaking Presentation on Cancer Vaccines
Evaxion Biotech A/S (NASDAQ: EVAX), a pioneer in the TechBio sector focused on AI-powered vaccine development, is set to present significant preclinical data at the ESMO Immuno-Oncology Congress. This event is an excellent platform for showcasing innovations in cancer treatment and precision medicine.
Understanding the Unique Approach to Cancer Vaccination
The upcoming presentation will demonstrate Evaxion's innovative approach, which centers around precision cancer vaccines targeting non-conventional ERV (endogenous retrovirus) tumor antigens. These antigens are unique in that they can be found across different patients, allowing for the development of broadly effective therapies.
Data from Cutting-Edge Research
The research data to be disclosed originates from thorough studies involving human cells along with mouse tumor models. This dual focus allows researchers to observe human T-cell responses closely while also measuring the inhibition of tumor growth in animal models. Such comprehensive studies assist in affirming the effectiveness of their AI-Immunology™ platform in creating these precise vaccine targets.
The Potential of AI-Immunology™
Central to Evaxion's development process is their proprietary AI-Immunology™ platform. This advanced system intelligently identifies suitable ERV antigens, paving the way for constructing precision therapeutic vaccines tailored for various cancer types. This technological leap holds the promise of benefitting patients who have previously been unresponsive to standard immunotherapy methods.
Advantages of ERV Targeting
Utilizing endogenous retroviruses as focal points for vaccine design represents a fundamental shift in vaccine strategy. This approach not only broadens the potential patient base but also accommodates diverse immune system profiles, enhancing the prospect of successful treatments across a wider demographic. Evaxion intends to leverage this preclinically validated methodology to create new precision vaccine candidates, further enriching their existing personalized vaccine pipeline.
Conference Presentation Highlights
During the congress, Evaxion’s presentation will highlight the promising aspects of their cancer vaccine development:
- Abstract Title: AI-designed cancer vaccines: antigens from the dark genome are promising cancer vaccine targets
- Poster Number: 124P
- Location: Foyer Mezzanine
- Date/Time: December 12, 2024, at 12:30 CET / 06:30 EST
- Presenter: Daniela Kleine-Kohlbrecher, Senior Project Manager at Evaxion
Contact Information
For those interested in further information, the contact details are as follows:
Evaxion Biotech A/S
Mads Kronborg
Vice President, Investor Relations & Communication
+45 53 54 82 96
Email: mak@evaxion-biotech.com
About Evaxion Biotech A/S
Evaxion Biotech is a forward-thinking TechBio entity that utilizes its AI platform, AI-Immunology™, to revolutionize how we understand the human immune system. By harnessing artificial intelligence, they are driving the next generation of immunotherapy development across various disease categories, including cancers and infectious diseases.
Frequently Asked Questions
What is Evaxion Biotech known for?
Evaxion Biotech specializes in developing AI-powered vaccines aimed at treating cancer and infectious diseases.
What is the main focus of Evaxion's research presented at the ESMO Congress?
The company will showcase their research on precision cancer vaccines targeting endogenous retrovirus tumor antigens.
How does AI-Immunology™ impact cancer vaccine development?
AI-Immunology™ optimizes the selection of effective ERV antigens, leading to advancements in personalized cancer therapies.
When and where will the presentation take place?
The presentation is scheduled for December 12, 2024, at the ESMO Immuno-Oncology Congress in Geneva, Switzerland.
Who will be presenting at the conference?
Daniela Kleine-Kohlbrecher, Senior Project Manager at Evaxion, will present the findings.
